FLWS
$2.54
(-0.78%)
ACCO
$4.34
(0.93%)
ARLP
$24.79
(1.06%)
AUIAF
$0.14
(0%)
AZZ
$139.15
(-0.17%)
BTBT
$1.54
(-5.52%)
BTM
$0.49
(0%)
CVKD
$0.95
(0.6%)
LCE:CA
$0.28
(3.7%)
COCP
$1.11
(-3.06%)
CDRO
$9.45
(-0.53%)
CVGI
$3
(1.35%)
LODE
$2.28
(0%)
CMTL
$1.25
(-5.3%)
CNDT
$1.64
(-0.61%)
CXW
$33.73
(0.9%)
CMLS
$0.01
(0%)
DRCT
$0.54
(-40.65%)
DLHC
$4.08
(0.74%)
SSP
$2.72
(-0.73%)
ELDN
$2.5
(0.4%)
EVC
$7.12
(-3.52%)
EDRY
$58.47
(4.63%)
ESEA
$73.05
(0.87%)
FAT
$0.16
(0%)
RAIL
$6.76
(-2.03%)
GDEV
$11.66
(8.36%)
GOVX
$0.32
(-0.06%)
GOCO
$0.3
(0%)
GHM
$90.48
(-1.1%)
GLDD
$17
(0%)
GYRE
$7.35
(3.38%)
HMENF
$1.59
(0.63%)
III
$5.82
(2.11%)
IPOOF
$11.93
(1.1%)
KELYA
$15.8
(0.51%)
KTOS
$42.02
(-2.44%)
LUCK
$5.26
(-0.57%)
MAIA
$1.18
(-0.84%)
MGROF
$0.31
(0%)
NTRB
$7.47
(2.61%)
OCGN
$1.04
(1.96%)
PERF
$1.92
(0.52%)
QMCI
$0.15
(0%)
RGP
$3.74
(-3.86%)
SGA
$8.36
(-1.3%)
SHWZ
$0
(0%)
SHIP
$17.67
(-0.84%)
SLQT
$0.42
(1.92%)
SKYX
$1.15
(-2.54%)
SNAL
$2.3
(5.99%)
GEO
$32.34
(3.13%)
ODP
$28
(0%)
TNXP
$8.07
(-9.43%)
TSQ
$4.44
(-2.42%)
TZOO
$5.38
(3.26%)
UNCY
$4.19
(-0.71%)
VVX
$70.87
(0.11%)
VNCE
$11.44
(8.9%)
XELB
$0.64
(-3.04%)
ZOMDF
$0.08
(6.5%)
‌
10/5/2026

Gate Bioscience Expands Its Lilly Deal to More Than $870 Million, Adding a New Drug Target

Gate Bioscience, a privately held drug discovery company, announced Monday that it has expanded its research and licensing agreement with Eli Lilly (NYSE: LLY) in a deal now potentially worth more than $870 million. The original agreement, announced in July 2025, was worth up to $856 million. The expansion adds one drug target, with an option to add a second.

0
3 min read
  • ‌
    Noble Capital Markets Research Morning Call

    Noble Capital Markets Research Morning Call

    Today’s Noble Capital Markets equity research reports, available with free Chann...

    127 min read
  • Amazon Just Hit Its Lowest Valuation Ever as a Public Company

    3 min read
  • Broadcom Will Lend Anthropic Up to $42 Billion. It’s the Third Big Tech Company Doing This

    3 min read

News

10/5/2026

Release – NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

16 min read
‌
Release – NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
10/5/2026

Release – Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

2 min read
‌
Release – Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
10/5/2026

Release – Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth

9 min read
‌
Release – Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
10/5/2026

Release – Kratos Secures More Than $100 Million in Contracts for Space and Cyber Mission Capabilities

5 min read
‌
Release – Kratos Secures More Than $100 Million in Contracts for Space and Cyber Mission Capabilities

Video Content

  • ‌
    Noble Roman's

    Noble Roman's

    Conference Presentation
    10/2/2026
  • ‌
    Collective Mining

    Collective Mining

    Conference Presentation
    10/2/2026
  • ‌
    Grid Metals

    Grid Metals

    Conference Presentation
    10/2/2026
  • ‌
    First Phosphate

    First Phosphate

    Conference Presentation
    10/2/2026
  • Movers

    Symbol
    Change
    PDSB
    60.32%
    RETO
    25.81%
    CMCT
    22.63%
    RXO
    22.54%
    INTT
    22.28%